

DAFTAR PUSTAKA

- Aps, L.R. de M.M. *et al.* (2018) "Adverse events of vaccines and the consequences of non-vaccination: A critical review," *Revista de Saude Publica*, 52, pp. 1–13. Available at: <https://doi.org/10.11606/S1518-8787.2018052000384>.
- Bae, S. *et al.* (2021) "Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea," *Journal of Korean Medical Science*, 36(17), pp. 1–9. Available at: <https://doi.org/10.3346/jkms.2021.36.e115>.
- Barański, K. *et al.* (2019) "Parental declaration of adverse event following immunization in a cross-sectional study in Poland," *International Journal of Environmental Research and Public Health*, 16(20). Available at: <https://doi.org/10.3390/ijerph16204038>.
- Bihua Han*, Yufei Song*, Changgui Li*, Wanqi Yang, Qingxia Ma, Zhiwei Jiang, Minjie Li, Xiaojuan Lian, Wenbin Jiao, Lei Wang, Qun Shu, Zhiwei Wu, Yuliang Zhao, Qi Li, Q.G. (2020) "Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial," *Ann Oncol*, 7(May), pp. 19–21.
- Bursac, Z. *et al.* (2008) "Purposeful selection of variables in logistic regression," *Source Code for Biology and Medicine*, 3. Available at: <https://doi.org/10.1186/1751-0473-3-17>.
- CDC (2022) "Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States," *Centers for Disease Control and Prevention*, 0, pp. 1–5. Available at: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html>.
- Danova, J., Kocourkova, A. and Celko, A.M. (2017) "Active surveillance study of adverse events following immunisation of children in the Czech Republic," *BMC Public Health*, 17(1), pp. 1–5. Available at: <https://doi.org/10.1186/s12889-017-4083-4>.
- Dethan, C.M. and Suariyani, N.L.P. (2017) "PENGETAHUAN DAN SIKAP TENTANG PERILAKU VAKSINASI HPV PADA SISWI SMA SWASTA," *Media Kesehatan Masyarakat Indonesia*, 13(2), p. 167. Available at: <https://doi.org/10.30597/mkmi.v13i2.1989>.
- Fadilah, S. *et al.* (2022) "Factors Associated with Adverse Events Following the First Dose of COVID-19 Immunization in Indonesia," *Korean Journal of Adult Nursing*, 34(3), pp. 249–257.
- Grace, C. (2020) "Manifestasi Klinis dan Perjalanan Penyakit pada Pasien Covid-19," *Majority*, 9, pp. 49–55.
- Kao, C.M., Orenstein, W.A. and Anderson, E.J. (2021) "The Importance of Advancing Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Children," *Clinical Infectious Diseases*, 72(3), pp. 515–518. Available at: <https://doi.org/10.1093/cid/ciaa712>.

- Kaur, R.J. *et al.* (2021) “Adverse Events Reported From COVID-19 Vaccine Trials: A Systematic Review,” *Indian Journal of Clinical Biochemistry* [Preprint]. Available at: <https://doi.org/10.1007/s12291-021-00968-z>.
- Kemendes RI (2017) “PERATURAN MENTERI KESEHATAN REPUBLIK INDONESIA NOMOR 12 TAHUN 2017 TENTANG PENYELENGGARAAN IMUNISASI,” *Kementerian Kesehatan Republik Indonesia*, 549, pp. 40–42.
- Kemendes RI. (2021) “Pmk No 10 Tahun 2021 tentang PELAKSANAAN VAKSINASI DALAM RANGKA PENANGGULANGAN PANDEMI CORONA VIRUS DISEASE 2019 (COVID-19),” *Permenkes RI*, 2019, p. 33. Available at: <https://persi.or.id/wp-content/uploads/2021/02/pmk10-2021.pdf>.
- _____. (2021) *Vaksinasi COVID-19 untuk Anak Usia 6-11 Tahun dimulai 14 Desember*, <https://sehatnegeriku.kemkes.go.id/baca/rilis-media/20211212/1938972/vaksinasi-covid-19-untuk-anak-usia-6-11-tahun-dimulai-14-desember/>. Available at: <https://sehatnegeriku.kemkes.go.id/baca/rilis-media/20211212/1938972/vaksinasi-covid-19-untuk-anak-usia-6-11-tahun-dimulai-14-desember/> (Accessed: June 25, 2022).
- _____. (2021) “KEPUTUSAN MENTERI KESEHATAN REPUBLIK INDONESIA NOMOR HK.01.07/MENKES/6688/2021 TENTANG PELAKSANAAN VAKSINASI CORONA VIRUS DISEASE 2019 (COVID-19) BAGI ANAK USIA 6 (ENAM) SAMPAI DENGAN 11 (SEBELAS) TAHUN.”
- _____. (2020) “Keputusan Direktur Jenderal Pencegahan dan Pengendalian Penyakit Nomor Hk.02.02/4/1/2021 tentang Petunjuk Teknis Pelaksanaan Vaksinasi dalam Rangka Penanggulangan Pandemi Corona Virus Disease 2019 (COVID-19),” *Kementerian Kesehatan RI*, 4247608(021), p. 114. Available at: <https://www.kemkes.go.id/article/view/19093000001/penyakit-jantung-penyebab-kematian-terbanyak-ke-2-di-indonesia.html>.
- Kim, M.A. *et al.* (2021) “COVID-19 vaccine-associated anaphylaxis and allergic reactions: Consensus statements of the KAAACI urticaria/angioedema/anaphylaxis working group,” *Allergy, Asthma and Immunology Research*. Korean Academy of Asthma, Allergy and Clinical Immunology, pp. 526–544. Available at: <https://doi.org/10.4168/aair.2021.13.4.526>.
- Lazarus, R. *et al.* (2021) “Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial,” *The Lancet*, 398(10318), pp. 2277–2287. Available at: [https://doi.org/10.1016/S0140-6736\(21\)02329-1](https://doi.org/10.1016/S0140-6736(21)02329-1).
- Lingappan, K. *et al.* (2020) “Understanding the age divide in COVID-19: why are children overwhelmingly spared?,” *Am J Physiol Lung Cell Mol Physiol*, 319, pp. 39–44. Available at: <https://doi.org/10.1152/ajplung.00183.2020>. -The.

- Loharikar, A. *et al.* (2018) “Anxiety-related adverse events following immunization (AEFI): A systematic review of published clusters of illness,” *Vaccine*, 36(2), pp. 299–305. Available at: <https://doi.org/10.1016/j.vaccine.2017.11.017>.
- Lopes, S.R.C. *et al.* (2018) “Adverse events following immunization in Brazil: Age of child and vaccine-associated risk analysis using logistic regression,” *International Journal of Environmental Research and Public Health*, 15(6). Available at: <https://doi.org/10.3390/ijerph15061149>.
- Mohamadian, M. *et al.* (2021) “COVID-19: Virology, biology and novel laboratory diagnosis,” *Journal of Gene Medicine*. Blackwell Publishing Inc. Available at: <https://doi.org/10.1002/jgm.3303>.
- Nilsson, L. *et al.* (2017) “Vaccination and allergy: EAACI position paper, practical aspects,” *Pediatric Allergy and Immunology*, 28(7), pp. 628–640. Available at: <https://doi.org/10.1111/pai.12762>.
- Pawar, P.N. *et al.* (2022) “To Study Adverse Effect following Immunization (AEFI) and COVID-19 Infection amongst COVID-19 Vaccine Benefeciaries,” *Journal of Association of Physicians of India*, 70(2), pp. 20–22.
- Riad, A. *et al.* (2021) “Article prevalence and risk factors of coronavac side effects: An independent cross-sectional study among healthcare workers in turkey,” *Journal of Clinical Medicine*, 10(12). Available at: <https://doi.org/10.3390/jcm10122629>.
- Rizwan, W. *et al.* (2022) “Safety Profile of Sinopharm COVID-19 Vaccine and Breakthrough Infections in Pakistan.” Available at: <https://doi.org/10.1101/2022.01.18.22268965>.
- Rzyski, P. *et al.* (2021) “The Perception and Attitudes toward COVID-19 Vaccines: A Cross-Sectional Study in Poland.” Available at: <https://doi.org/10.3390/vaccines9040382>.
- Saadi, N. *et al.* (2021) “Models of COVID-19 vaccine prioritisation: a systematic literature search and narrative review,” *BMC Medicine*. BioMed Central Ltd. Available at: <https://doi.org/10.1186/s12916-021-02190-3>.
- Seck I, Diop B, Leyé MM, Mbacké Mboup B, Ndiaye A, Seck PA, Doucoure A, Ba TA, Diongue M, Faye A, T.D.A. (2016) “Social Determinants of Routine Immunization Coverage of Children Aged 12 to 23 Months in the Kaolack Region of Senegal,” *Sante Publique*, 28(6), pp. 807–815.
- Spencer, J.P., Trondsen Pawlowski, R.H. and Thomas, S. (2017) *Vaccine Adverse Events: Separating Myth from Reality, Number*. Available at: www.aafp.org/afp.
- Tanriover, M.D. *et al.* (2020) “Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey,” (January), pp. 19–21.
- Thanh Le, T. *et al.* (2020) “The COVID-19 vaccine development landscape,” *Nature reviews. Drug discovery*. NLM (Medline), pp. 305–306. Available at: <https://doi.org/10.1038/d41573-020-00073-5>.
- Toback, S. *et al.* (2022) “Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-

- controlled, phase 3 trial,” *The Lancet Respiratory Medicine*, 10(2), pp. 167–179. Available at: [https://doi.org/10.1016/S2213-2600\(21\)00409-4](https://doi.org/10.1016/S2213-2600(21)00409-4).
- Turner, P.J. *et al.* (2021) “COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee,” *World Allergy Organization Journal*. Elsevier Inc. Available at: <https://doi.org/10.1016/j.waojou.2021.100517>.
- Umakanthan, S. *et al.* (2020) “Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19),” *Postgraduate Medical Journal*. BMJ Publishing Group, pp. 753–758. Available at: <https://doi.org/10.1136/postgradmedj-2020-138234>.
- WHO (2018) *Causality assessment of an adverse event following immunization*, World Health Organization.
- WHO. (2021) “Fact sheet for health workers: Sinovac-CoronaVac COVID-19 vaccine,” *Who*, 19(July), pp. 2–4. Available at: <https://apps.who.int/iris/bitstream/handle/10665/343396/WHO-EURO-2021-2913-42671-59457-eng.pdf>.
- _____. (2021) “Keamanan Vaksin Dalam Program Imunisasi,” *Dasar-Dasar Keamanan Vaksin*, World Health Organization, pp. 20–21. Available at: <https://in.vaccine-safety-training.org/vaccine-safety-in-immunization-programmes.html>.
- Wilson, K., Ducharme, R. and Hawken, S. (2013) “Association between socioeconomic status and adverse events following immunization at 2, 4, 6 and 12 months,” *Human Vaccines and Immunotherapeutics*, 9(5), pp. 1153–1157. Available at: <https://doi.org/10.4161/hv.23533>.
- Xia, S. *et al.* (2021) “Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial,” *The Lancet Infectious Diseases*, 21(1), pp. 39–51. Available at: [https://doi.org/10.1016/S1473-3099\(20\)30831-8](https://doi.org/10.1016/S1473-3099(20)30831-8).
- Zafack, J.G. *et al.* (2017) “Risk of recurrence of adverse events following immunization: A systematic review,” *Pediatrics*, 140(3). Available at: <https://doi.org/10.1542/peds.2016-3707>.
- _____. *et al.* (2019) “Rate of Recurrence of Adverse Events Following Immunization: Results of 19 Years of Surveillance in Quebec, Canada,” *Pediatric Infectious Disease Journal*, 38(4), pp. 377–383. Available at: <https://doi.org/10.1097/INF.0000000000002162>.
- Zhao, Y. *et al.* (2020) “Single-Cell RNA Expression Profiling of ACE2, the Receptor of SARS-CoV-2,” *American Journal of Respiratory and Critical Care Medicine*, 202(5), pp. 756–759. Available at: <https://doi.org/10.1164/rccm.202001-0179LE>.